InvestorsHub Logo
Followers 2
Posts 379
Boards Moderated 0
Alias Born 12/04/2016

Re: gr8db8 post# 1007

Tuesday, 06/06/2017 12:54:04 PM

Tuesday, June 06, 2017 12:54:04 PM

Post# of 2099
That is true but still it doesn't contradict my claims which is well known to the medical community. Vbl need to know the facts about their drug and avastin and I hope I m wrong but it looks like they don't know how to design the trials. Many mistakes ...another example is changing treatment in progression ...they know their drug is not good at stopping progression so why to determine changes in treatment upon progression...moreover they know it takes time for the drug to work so why not to change treatment after 4 shots of vb111 even if there is progression. Another example they see only 50% of patients react with fever and they live double the time patients without fever lives. Actually non fever live avastin time so I believe there is almost zero benefit from the antiangiogenesis other words u see that..wont u stop and think moment maybe if we treat a soup of many types of viruses isn't it going to raise fever response? Of course it will...instead they go for car-t treat except of improving the already working drug vb111. Anyway I look at it any direction I see huge mistakes and stupidity sorry marketing...decisions ...technology...design of trial...
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News